The use of cryopreserved aortoiliac allograft for aortic reconstruction in the United States.
BACKGROUND
Aortic infections, even with treatment, have a high mortality and risk of recurrent infection and limb loss. Cryopreserved aortoiliac allograft (CAA) has been proposed for aortic reconstruction to improve outcomes in this high-risk population.


METHODS
A multicenter study using a standardized database was performed at 14 of the 20 highest volume institutions that used CAA for aortic reconstruction in the setting of infection or those at high risk for prosthetic graft infection.


RESULTS
Two hundred twenty patients (mean age, 65; male:female, 1.6/1) were treated since 2002 for culture positive aortic graft infection (60%), culture negative aortic graft infection (16%), enteric fistula/erosion (15%), infected pseudoaneurysm adjacent to the aortic graft (4%), and other (4%). Intraop cultures indicated infection in 66%. Distal anastomosis was to the femoral artery and iliac. Mean hospital length of stay was 24 days, and 30-day mortality was 9%. Complications occurred in 24% and included persistent sepsis (n = 17), CAA thrombosis (n = 9), CAA rupture (n = 8), recurrent CAA/aortic infection (n = 8), CAA pseudoaneurysm (n = 6), recurrence of aortoenteric fistula (n = 4), and compartment syndrome (n = 1). Patients with full graft excision had significantly better outcomes. Ten (5%) patients required allograft explant. Mean follow-up was 30 ± 3 months. Freedom from graft-related complications, graft explant, and limb loss was 80%, 88%, and 97%, respectively, at 5 years. Primary graft patency was 97% at 5 years, and patient survival was 75% at 1 year and 51% at 5 years.


CONCLUSIONS
This largest study of CAA indicates that CAA allows aortic reconstruction in the setting of infection or those at high risk for infection with lower early and long-term morbidity and mortality than other previously reported treatment options. Repair with CAA is associated with low rates of aneurysm formation, recurrent infection, aortic blowout, and limb loss. We believe that CAA should be considered a first line treatment of aortic infections.
Division of Vascular Surgery, University of California Los Angeles, Los Angeles, Calif.
Michael P
MP
Harlander-Locke
Division of Vascular Surgery, University of California Los Angeles, Los Angeles, Calif.
Liv K
LK
Harmon
Division of Vascular Surgery, University of California Los Angeles, Los Angeles, Calif. Electronic address: pflawrence@mednet.ucla.edu.
Peter F
PF
Lawrence
Division of Vascular Surgery, Mayo Clinic, Rochester, Minn.
Gustavo S
GS
Oderich
Division of Vascular Surgery, Indiana University, Indianapolis, Ind.
Robert A
RA
McCready
St. Vincent Heart and Vascular, Billings, Mont.
Mark D
MD
Morasch
Division of Vascular Surgery, University of Florida, Gainesville, Fla.
Robert J
RJ
Feezor
Wei
W
Zhou
Jean
J
Bismuth
William C
WC
Pevec
Mateus P
MP
Correa
Jeffrey
J
Jim
Joseph S
JS
Ladowski
Panagiotis
P
Kougias
Paul G
PG
Bove
Catherine M
CM
Wittgen
John V
JV
White
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D064591:Allografts; D001011:Aorta / Q000637:transplantation*; D001807:Blood Vessel Prosthesis / Q000009:adverse effects*; D019917:Blood Vessel Prosthesis Implantation / Q000009:adverse effects* / Q000295:instrumentation / Q000401:mortality; D015925:Cryopreservation; D020878:Device Removal; D005260:Female; D061847:Hospitals, High-Volume; D006801:Humans; D007083:Iliac Artery / Q000637:transplantation*; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D016459:Prosthesis-Related Infections / Q000175:diagnosis / Q000382:microbiology / Q000401:mortality / Q000601:surgery*; D019651:Plastic Surgery Procedures / Q000009:adverse effects / Q000401:mortality; D012086:Reoperation; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States